Drug Information

Drug General Information
Drug ID
D04HAF
Former ID
DIB009072
Drug Name
LY-2624803
Synonyms
HY-10275; Insomnia therapy, Hypnion; Insomnia therapy, Lilly; Dual-acting oral H1 receptor inverse agonist/5-HT 2a receptor modulator (insomnia), Hypnion; Dual-acting oral H1 receptor inverse agonist/5-HT 2a receptor modulator (insomnia), Lilly
Indication Insomnia [ICD9: 307.41, 307.42, 327.0, 780.51, 780.52; ICD10:F51.0, G47.0] Phase 2 [522475]
Company
Hypnion
Structure
Download
2D MOL

3D MOL
Target and Pathway
Target(s) Histamine H1 receptor Target Info Modulator [533039]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Inflammatory mediator regulation of TRP channels
PANTHER Pathway Histamine H1 receptor mediated signaling pathway
Reactome Histamine receptors
G alpha (q) signalling events
WikiPathways Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
IL-4 Signaling Pathway
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
References
Ref 522475ClinicalTrials.gov (NCT00784875) An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia. U.S. National Institutes of Health.
Ref 533039Current Phase II investigational therapies for insomnia. Expert Opin Investig Drugs. 2015 Mar;24(3):401-11.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.